Novartis is making strong immunology portfolio by investing in immunological diseases such as spanning hidradenitis suppurativa (HS), chronic spontaneous urticaria (CSU), Sjogrens syndrome, axial spondyloarthritis, and psoriasis.
Novartis will showcase data from its leading immunology portfolio and emerging pipeline at the upcoming 31st European Academy of Dermatology and Venereology (EADV) Congress and the 15th International Symposium on September 7–10, 2022.
Novartis will exhibit total of 37 abstracts will be shared across both meetings, spanning hidradenitis suppurativa (HS), chronic spontaneous urticaria (CSU), Sjogren’s syndrome, axial spondyloarthritis, and psoriasis.
The Novartis ambition is eyeing on immunological conditions, which affect up to 4.5% of the world’s population and can have a significant impact on quality of life. In addition to its comprehensive portfolio of innovative therapy options, Novartis is exploring potential biologic and oral treatments with various mechanisms of action in HS, developing medicines that could help those living with CSU achieve complete symptom control, and advancing research in Sjogren’s syndrome, for which there are currently no disease-modifying treatments available.
Novartis will also share the latest findings from a number of patient-based initiatives at EADV, including the global Psoriasis and Beyond study exploring the impact of psoriatic disease on mental health. Results from a comprehensive social media monitoring program to help illuminate the significant unmet needs of people living with HS will also be presented.
Novartis already has FDA approved immunolgical medicines such as Cosentyx for psoriatic disease and axial spondyloarthritis , Xolair for chronic urticaria, and Ilaris for a number of rare autoinflammatory diseases.
